
Dexamethasone palmitate
CAS No. 14899-36-6
Dexamethasone palmitate( DXP )
Catalog No. M26663 CAS No. 14899-36-6
Dexamethasone palmitate, a lipophilic prodrug of Dexamethasone, shows a 47-fold lower affinity for the glucocorticoid receptor than Dexamethasone.
Purity : >98% (HPLC)






Size | Price / USD | Stock | Quantity |
5MG | 39 | Get Quote |
![]() ![]() |
10MG | 63 | Get Quote |
![]() ![]() |
25MG | 101 | Get Quote |
![]() ![]() |
50MG | 138 | Get Quote |
![]() ![]() |
100MG | 237 | Get Quote |
![]() ![]() |
200MG | 353 | Get Quote |
![]() ![]() |
500MG | Get Quote | Get Quote |
![]() ![]() |
1G | Get Quote | Get Quote |
![]() ![]() |
Biological Information
-
Product NameDexamethasone palmitate
-
NoteResearch use only, not for human use.
-
Brief DescriptionDexamethasone palmitate, a lipophilic prodrug of Dexamethasone, shows a 47-fold lower affinity for the glucocorticoid receptor than Dexamethasone.
-
DescriptionDexamethasone palmitate, a lipophilic prodrug of Dexamethasone, shows a 47-fold lower affinity for the glucocorticoid receptor than Dexamethasone. Dexamethasone palmitate is a glucocorticoid receptor agonist and an anti-inflammatory agent.(In Vivo):In a murine collagen-induced arthritis model, their passive accumulation in arthritic joints leads to disease remission and recovery of the joint structure at a dose of 1 mg/kg dexamethasone, without any adverse effects.
-
In VitroDexamethasone palmitate (100 μg/mL; 48 h) affects cytokines concentration of RAW 264.7 cells.Cell Viability Assay Cell Line:RAW 264.7 cells Concentration:100 μg/mL Incubation Time:48 hours Result:Showed vitro anti-inflammatory effects and decreased LPS-induced MCP-1 and TNF-α concentration in RAW 264.7 cells.
-
In VivoDexamethasone palmitate (1280 μg; IVT injection once) shows different distribution in ocular tissue at different times.Dexamethasone palmitate (280-1280 μg; IVT injection once) affects VEGF-induced vascular hyperpermeability. Animal Model:New Zealand White rabbitsDosage:1280 μgAdministration:IVT injection; 1280 μg onceResult:Mostly distributed in vitreous and still existed till 9 months. The least distributed in aqueous humor and almost disappeared till 6 months.Animal Model:New Zealand White rabbits with VEGF injectionDosage:280, 560 and 1280 μg Administration:IVT injection; 280-1280 μg once Result:After 9 months administration VEGF-induced vascular permeability was controlled at a concentration of 1280 μg, besides 280 and 560 μg also reduced VEGF-induced vascular hyperpermeability after administration for 4 months.
-
SynonymsDXP
-
PathwayCytoskeleton/Cell Adhesion Molecules
-
TargetGlucokinase
-
RecptorPEGs
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number14899-36-6
-
Formula Weight630.882
-
Molecular FormulaC38H59FO6
-
Purity>98% (HPLC)
-
SolubilityIn Vitro:?DMSO : 50 mg/mL (79.26 mM)
-
SMILES[H][C@@]12C[C@@H](C)[C@](O)(C(=O)COC(=O)CCCCCCCCCCCCCCC)[C@@]1(C)C[C@H](O)[C@@]1(F)[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
-
Chemical Name——
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1.An S, et al. Small-molecule PROTACs: An emerging and promising approach for the development of targeted therapy drugs. EBioMedicine. 2018 Oct;36:553-562
molnova catalog



related products
-
Conduritol B epoxide
Conduritol B epoxide is an irreversible inhibitor of β-glucosidase (GCase).
-
Oxfendazole
Oxfendazole is a broad spectrum benzimidazole anthelmintic.
-
Diosbulbin B
Diosbulbin B has potential anti-tumor effects which may be related to influencing the immune system for the first time.